Загрузка...
AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials
Epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) constitute the standard of care for stage IV EGFR mutated non-small cell lung cancer (NSCLC) patients initiating first-line systemic treatment. Despite the initial remarkable activity of targeted treatment in these patients re...
Сохранить в:
| Опубликовано в: : | Transl Lung Cancer Res |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
AME Publishing Company
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4758983/ https://ncbi.nlm.nih.gov/pubmed/26958497 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.07.02 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|